Inclusion Criteria:

          -  Signed informed written consent.

          -  Gender: female.

          -  Age: 18-55 years at time of signing consent.

          -  BMI of subjects: < 45 kg/m2.

          -  Uterine fibroids:

          -  Diagnosed by ultrasound (MRI will be used only if ultrasound is inconclusive).

          -  Number: any number of fibroids.

          -  Location: submucosal or intramural.

          -  At least one fibroid of diameter > 3cm.

          -  Symptoms: one or more of the following symptoms of heavy menstrual bleeding (HMB),
             defined as: Experienced cyclic (22 to 35 days) abnormal uterine bleeding (heavy or
             prolonged) in at least 3 of the last 6 menstrual periods, including menstrual bleeding
             lasting 5 or more days or heavy bleeding per participant recall. Examples of heavy
             bleeding may include, but are not limited to the following:

          -  Requires the use of double protection to manage menstrual bleeding.

          -  Menstrual bleeding accompanied by the sensation of "gushing" or "flooding".

          -  Saturates more than 1 tampon or sanitary pad per hour for 3 or more consecutive hours.

          -  Regularly needs to change the tampon or sanitary pad at night or regularly soils
             bedclothes.

          -  Heavy bleeding that affects work, school, or social activities.

          -  Pelvic pain/ pressure likely caused by fibroids.

          -  Plan for surgery (hysterectomy or myomectomy).

          -  Normal Pap smear within the last year.

          -  Use of contraception during study such as non-hormonal oral contraceptives,
             intrauterine devices (IUD)/ intrauterine systems (IUS), barrier contraceptives,
             abstinence or sterilization.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Previous or current uterine, cervical or ovarian cancer.

          -  Current endometrial hyperplasia or history of atypical endometrial hyperplasia.
             Endometrial biopsy will be done during screening (if not done within last 12 months).

          -  Suspicion of leiomyosarcoma.

          -  Recent rapid growth of fibroids (i.e. doubling in size within 1-6 months period).

          -  Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical
             dysplasia, or abnormal adnexal/ovarian mass).

          -  Menopausal status.

          -  Surgery is urgently indicated (< 3 months) for medical or social reasons.

          -  Hemoglobin ≤ 6 g/dL.

          -  Currently enrolled in another investigational study.

          -  Mental condition or other barrier preventing informed written consent.

          -  Allergy or hypersensitivity to simvastatin.

          -  Current use of simvastatin or other drugs of the same class.

          -  Concomitant administration of strong CYP3A4 inhibitors including itraconazole,
             ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin,
             HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and cobicistat-containing
             products.

          -  Concomitant administration of gemfibrozil, cyclosporine, or danazol, verapamil,
             diltiazem, amiodarone, diltiazem, dronedarone, amlodipine, ranolazine, lomitapide, and
             grapefruit juice.

          -  Active liver disease, which may include unexplained persistent elevations in hepatic
             transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase
             > 2 s.d. above the normal range at screening visit)

          -  Known increased risk or diagnosis of a myopathy.